Synergistic Radiosensitization by Gold Nanoparticles and the Histone Deacetylase Inhibitor SAHA in 2D and 3D Cancer Cell Cultures
Abstract
:1. Introduction
2. Materials and Methods
2.1. Synthesis and Characterization of Gold Nanoparticles (AuNPs)
2.2. Cell Culture
2.3. Electron Microscopy
2.4. Irradiation
2.5. Viability Assay
2.6. Clonogenic Assay
3. Immunocytochemistry
4. Immunohistochemistry
5. Results
5.1. Synthesis and Characterization of AuNPs
5.2. The Internalized AuNPs Do Not Affect the Histone Deacetylase-Inhibiting Activity of Suberoylanilide Hydroxamic Acid (SAHA) in Cancer Cells
5.3. AuNPs and SAHA in Combination Synergistically Decrease Cancer Cell Viability After Irradiation
5.4. Combinational Treatments Decrease the Colony Forming Capabilities and Increase the DNA Damage in Cancer Cells
5.5. Combinational Treatment Enhances Radiosensitivity of Tumor Cells in 3D
6. Discussion
Supplementary Materials
Author Contributions
Funding
Acknowledgments
Conflicts of Interest
References
- Nurgali, K.; Jagoe, R.T.; Abalo, R. Adverse effects of cancer chemotherapy: Anything new to improve tolerance and reduce sequelae? Front. Pharmacol. 2018, 9, 245. [Google Scholar] [CrossRef] [PubMed]
- Guais, A.; Baronzio, G.F.; Sanders, E.; Campion, F.; Mainini, C.; Fiorentini, G.; Montagnani, F.; Behzadi, M.; Schwartz, L.; Abolhassani, M. Adding a combination of hydroxycitrate and lipoic acid (METABLOCTM) to chemotherapy improves effectiveness against tumor development: Experimental results and case report. Investig. New Drugs 2012, 30, 200–211. [Google Scholar] [CrossRef] [PubMed]
- Robert, N.; Leyland-Jones, B.; Asmar, L.; Belt, R.; Llegbodu, D.; Loesch, D.; Raju, R.; Valentine, E.; Sayre, R.; Cobleigh, M.; et al. Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-Overexpressing metastatic breast cancer. J. Clin. Oncol. 2006, 24, 2786–2792. [Google Scholar] [CrossRef] [PubMed]
- Forastiere, A.A.; Goepfert, H.; Maor, M.; Pajak, T.F.; Weber, R.; Morrison, W.; Glisson, B.; Trotti, A.; Ridge, J.A.; Chao, C.; et al. Concurrent Chemotherapy and Radiotherapy for Organ Preservation in Advanced Laryngeal Cancer. N. Engl. J. Med. 2003, 349, 2091–2098. [Google Scholar] [CrossRef] [Green Version]
- Miller, T.P.; Dahlberg, S.; Cassady, J.R.; Adelstein, D.J.; Spier, C.M.; Grogan, T.M.; LeBlanc, M.; Carlin, S.; Chase, E.; Fisher, R.I. Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin’s lymphoma. N. Engl. J. Med. 1998, 339, 21–26. [Google Scholar] [CrossRef] [Green Version]
- Hogberg, T.; Signorelli, M.; De Oliveira, C.F.; Fossati, R.; Lissoni, A.A.; Sorbe, B.; Andersson, H.; Grenman, S.; Lundgren, C.; Rosenberg, P.; et al. Sequential adjuvant chemotherapy and radiotherapy in endometrial cancer-Results from two randomised studies. Eur. J. Cancer 2010, 46, 2422–2431. [Google Scholar] [CrossRef]
- Stupp, R.; Mason, W.P.; Van Den Bent, M.J.; Weller, M.; Fisher, B.; Taphoorn, M.J.B.; Belanger, K.; Brandes, A.A.; Marosi, C.; Bogdahn, U.; et al. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005, 352, 987–996. [Google Scholar] [CrossRef]
- Bernier, J.; Hall, E.J.; Giaccia, A. Radiation oncology: A century of achievements. Nat. Rev. Cancer 2004, 4, 737–747. [Google Scholar] [CrossRef]
- Dewey, W.C.; Ling, C.C.; Meyn, R.E. Radiation-induced apoptosis: Relevance to radiotherapy. Int. J. Radiat. Oncol. Biol. Phys. 1995, 33, 781–796. [Google Scholar] [CrossRef]
- Prise, K.M.; Schettino, G.; Folkard, M.; Held, K.D. New insights on cell death from radiation exposure. Lancet Oncol. 2005, 6, 520–528. [Google Scholar] [CrossRef]
- Wardman, P. Chemical Radiosensitizers for Use in Radiotherapy. Clin. Oncol. 2007, 19, 397–417. [Google Scholar] [CrossRef] [PubMed]
- Biade, S.; Stobbe, C.C.; Boyd, J.T.; Chapman, J.D. Chemical agents that promote chromatin compaction radiosensitize tumour cells. Int. J. Radiat. Biol. 2001, 77, 1033–1042. [Google Scholar] [CrossRef] [PubMed]
- Liu, Y.; Zhang, P.; Li, F.; Jin, X.; Li, J.; Chen, W.; Li, Q. Metal-based NanoEnhancers for future radiotherapy: Radiosensitizing and synergistic effects on tumor cells. Theranostics 2018, 8, 1824–1849. [Google Scholar] [CrossRef] [PubMed]
- Chithrani, D.B.; Jelveh, S.; Jalali, F.; van Prooijen, M.; Allen, C.; Bristow, R.G.; Hill, R.P.; Jaffray, D.A. Gold Nanoparticles as Radiation Sensitizers in Cancer Therapy. Radiat. Res. 2010, 173, 719–728. [Google Scholar] [CrossRef]
- Zhang, X.F.; Liu, Z.G.; Shen, W.; Gurunathan, S. Silver nanoparticles: Synthesis, characterization, properties, applications, and therapeutic approaches. Int. J. Mol. Sci. 2016, 17, 1534. [Google Scholar] [CrossRef]
- Kim, M.S.; Lee, E.J.; Kim, J.W.; Chung, U.S.; Koh, W.G.; Keum, K.C.; Koom, W.S. Gold nanoparticles enhance anti-tumor effect of radiotherapy to hypoxic tumor. Radiat. Oncol. J. 2016, 34, 230–238. [Google Scholar] [CrossRef]
- Porcel, E.; Liehn, S.; Remita, H.; Usami, N.; Kobayashi, K.; Furusawa, Y.; Sech, C.L.; Lacombe, S. Platinum nanoparticles: A promising material for future cancer therapy? Nanotechnology 2010, 21, 85103. [Google Scholar] [CrossRef]
- Noguchi, Y.; Wu, J.; Duncan, R.; Strohalm, J.; Ulbrich, K.; Akaike, T.; Maeda, H. Early phase tumor accumulation of Macromolecules: A great difference in clearance rate between tumor and normal tissues. Jpn. J. Cancer Res. 1998, 89, 307–314. [Google Scholar] [CrossRef]
- Sherwood, L.M.; Parris, E.E.; Folkman, J. Tumor Angiogenesis: Therapeutic Implications. N. Engl. J. Med. 1971, 285, 1182–1186. [Google Scholar] [CrossRef] [PubMed]
- Su, Y.L.; Hu, S.H. Functional nanoparticles for tumor penetration of therapeutics. Pharmaceutics 2018, 10, 193. [Google Scholar] [CrossRef] [Green Version]
- Subiel, A.; Ashmore, R.; Schettino, G. Standards and methodologies for characterizing radiobiological impact of high-Z nanoparticles. Theranostics 2016, 6, 1651–1671. [Google Scholar] [CrossRef] [PubMed]
- Her, S.; Jaffray, D.A.; Allen, C. Gold nanoparticles for applications in cancer radiotherapy: Mechanisms and recent advancements. Adv. Drug Deliv. Rev. 2017, 109, 84–101. [Google Scholar] [CrossRef] [PubMed]
- Yang, X.; Yang, M.; Pang, B.; Vara, M.; Xia, Y. Gold Nanomaterials at Work in Biomedicine. Chem. Rev. 2015, 115, 10410–10488. [Google Scholar] [CrossRef] [PubMed]
- Ma, N.; Wu, F.G.; Zhang, X.; Jiang, Y.W.; Jia, H.R.; Wang, H.Y.; Li, Y.H.; Liu, P.; Gu, N.; Chen, Z. Shape-Dependent Radiosensitization Effect of Gold Nanostructures in Cancer Radiotherapy: Comparison of Gold Nanoparticles, Nanospikes, and Nanorods. ACS Appl. Mater. Interfaces 2017, 9, 13037–13048. [Google Scholar] [CrossRef]
- Dou, Y.; Guo, Y.; Li, X.; Li, X.; Wang, S.; Wang, L.; Lv, G.; Zhang, X.; Wang, H.; Gong, X.; et al. Size-Tuning Ionization to Optimize Gold Nanoparticles for Simultaneous Enhanced CT Imaging and Radiotherapy. ACS Nano 2016, 10, 2536–2548. [Google Scholar] [CrossRef]
- Cobley, C.M.; Chen, J.; Cho, E.C.; Wang, L.V.; Xia, Y. Gold nanostructures: A class of multifunctional materials for biomedical applications. Chem. Soc. Rev. 2011, 40, 44–56. [Google Scholar] [CrossRef] [Green Version]
- Herold, D.M.; Das, I.J.; Stobbe, C.C.; Iyer, R.V.; Chapman, J.D. Gold microspheres: A selective technique for producing biologically effective dose enhancement. Int. J. Radiat. Biol. 2000, 76, 1357–1364. [Google Scholar]
- Khan, F.M.; Werner, B.L. Validity of transition-zone dosimetry at high atomic number interfaces in megavoltage photon beams. Med. Phys. 1990, 17, 10–16. [Google Scholar]
- Werner, B.L.; Das, I.; Salk, W.N. Dose perturbations at interfaces in photon beams: Secondary electron transport. Med. Phys. 1990, 17, 212–226. [Google Scholar] [CrossRef]
- Das, I.J.; Chopra, K.L. Backscatter dose perturbation in kilovoltage photon beams at high atomic number interfaces. Med. Phys. 1995, 22, 767–773. [Google Scholar] [CrossRef]
- Rezaee, M.; Hill, R.P.; Jaffray, D.A. The Exploitation of Low-Energy Electrons in Cancer Treatment. Radiat. Res. 2017, 188, 123–143. [Google Scholar] [CrossRef] [PubMed]
- Chun, P. Histone deacetylase inhibitors in hematological malignancies and solid tumors. Arch. Pharm. Res. 2015, 38, 933–949. [Google Scholar] [CrossRef] [PubMed]
- Gerelchuluun, A.; Maeda, J.; Manabe, E.; Brents, C.A.; Sakae, T.; Fujimori, A.; Chen, D.J.; Tsuboi, K.; Kato, T.A. Histone deacetylase inhibitor induced radiation sensitization effects on human cancer cells after photon and hadron radiation exposure. Int. J. Mol. Sci. 2018, 19, 496. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Ryu, H.; Jin, H.; Ho, J.N.; Bae, J.; Lee, E.; Lee, S.E.; Lee, S. Suberoylanilide hydroxamic acid can re-sensitize a cisplatin-resistant human bladder cancer. Biol. Pharm. Bull. 2019, 42, 66–72. [Google Scholar] [CrossRef] [Green Version]
- Barneda-Zahonero, B.; Parra, M. Histone deacetylases and cancer. Mol. Oncol. 2012, 6, 579–589. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Marks, P.A.; Rifkind, R.A.; Richon, V.M.; Breslow, R.; Miller, T.; Kelly, W.K. Histone deacetylases and cancer: Causes and therapies. Nat. Rev. Cancer 2001, 1, 194–202. [Google Scholar] [CrossRef] [PubMed]
- Khan, O.; La Thangue, N.B. HDAC inhibitors in cancer biology: Emerging mechanisms and clinical applications. Immunol. Cell Biol. 2012, 90, 85–94. [Google Scholar] [CrossRef]
- Drazic, A.; Myklebust, L.M.; Ree, R.; Arnesen, T. The world of protein acetylation. Biochim. Biophys. Acta Proteins Proteom. 2016, 1864, 1372–1401. [Google Scholar] [CrossRef] [Green Version]
- Suzuki, J.; Chen, Y.Y.; Scott, G.K.; DeVries, S.; Chin, K.; Benz, C.C.; Waldman, F.M.; Hwang, E.S. Protein acetylation and histone deacetylase expression associated with malignant breast cancer progression. Clin. Cancer Res. 2009, 15, 3163–3171. [Google Scholar] [CrossRef] [Green Version]
- Minucci, S.; Pelicci, P.G. Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer 2006, 6, 38–51. [Google Scholar] [CrossRef] [Green Version]
- Cohen, H.Y.; Lavu, S.; Bitterman, K.J.; Hekking, B.; Imahiyerobo, T.A.; Miller, C.; Frye, R.; Ploegh, H.; Kessler, B.M.; Sinclair, D.A. Acetylation of the C terminus of Ku70 by CBP and PCAF controls Bax-Mediated apoptosis. Mol. Cell 2004, 13, 627–638. [Google Scholar] [CrossRef]
- Wang, R.; Cherukuri, P.; Luo, J. Activation of Stat3 sequence-specific DNA binding and transcription by p300/CREB-binding protein-mediated acetylation. J. Biol. Chem. 2005, 280, 11528–11534. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Yuan, Z.L.; Guan, Y.J.; Chatterjee, D.; Chin, Y.E. Stat3 dimerization regulated by reversible acetylation of a single lysine residue. Science 2005, 307, 269–273. [Google Scholar] [CrossRef] [PubMed]
- Bode, A.M.; Dong, Z. Post-translational modification of p53 in tumorigenesis. Nat. Rev. Cancer 2004, 4, 793–805. [Google Scholar] [CrossRef]
- Munshi, A.; Kurland, J.F.; Nishikawa, T.; Tanaka, T.; Hobbs, M.L.; Tucker, S.L.; Ismail, S.; Stevens, C.; Meyn, R.E. Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity. Clin. Cancer Res. 2005, 11, 4912–4922. [Google Scholar] [CrossRef] [Green Version]
- Chen, X.; Wong, P.; Radany, E.H.; Stark, J.M.; Laulier, C.; Wong, J.Y.C. Suberoylanilide hydroxamic acid as a radiosensitizer through modulation of RAD51 protein and inhibition of homology-directed repair in multiple myeloma. Mol. Cancer Res. 2012, 10, 1052–1064. [Google Scholar] [CrossRef] [Green Version]
- Lee, J.H.; Choy, M.L.; Ngo, L.; Foster, S.S.; Marks, P.A. Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair. Proc. Natl. Acad. Sci. USA 2010, 107, 14639–14644. [Google Scholar] [CrossRef] [Green Version]
- Karagiannis, T.C.; Kn, H.; El-Osta, A. Disparity of histone deacetylase inhibition on repair of radiation-induced DNA damage on euchromatin and constitutive heterochromatin compartments. Oncogene 2007, 26, 3963–3971. [Google Scholar] [CrossRef] [Green Version]
- Igaz, N.; Kovács, D.; Rázga, Z.; Kónya, Z.; Boros, I.M.; Kiricsi, M. Modulating chromatin structure and DNA accessibility by deacetylase inhibition enhances the anti-cancer activity of silver nanoparticles. Colloids Surf. B Biointerfaces 2016, 146, 670–677. [Google Scholar] [CrossRef]
- Ravi, M.; Paramesh, V.; Kaviya, S.R.; Anuradha, E.; Paul Solomon, F.D. 3D cell culture systems: Advantages and applications. J. Cell. Physiol. 2015, 230, 16–26. [Google Scholar] [CrossRef]
- Le Beyec, J.; Xu, R.; Lee, S.Y.; Nelson, C.M.; Rizki, A.; Alcaraz, J.; Bissell, M.J. Cell shape regulates global histone acetylation in human mammary epithelial cells. Exp. Cell Res. 2007, 313, 3066–3075. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Eke, I.; Cordes, N. Radiobiology goes 3D: How ECM and cell morphology impact on cell survival after irradiation. Radiother. Oncol. 2011, 99, 271–278. [Google Scholar] [CrossRef] [PubMed]
- Cordes, N.; Meineke, V. Cell adhesion-mediated radioresistance (CAM-RR): Extracellular matrix-dependent improvement of cell survival in human tumor and normal cells in vitro. Strahlenther. Onkol. 2003, 179, 337–344. [Google Scholar] [CrossRef]
- Hazlehurst, L.A.; Damiano, J.S.; Buyuksal, I.; Pledger, W.J.; Dalton, W.S. Adhesion to fibronectin via β1 integrins regulates p27kip1 levels and contributes to cell adhesion mediated drug resistance (CAM-DR). Oncogene 2000, 19, 4319–4327. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Roskelley, C.D.; Desprez, P.Y.; Bissell, M.J. Extracellular matrix-dependent tissue-specific gene expression in mammary epithelial cells requires both physical and biochemical signal transduction. Proc. Natl. Acad. Sci. USA 1994, 91, 12378–12382. [Google Scholar] [CrossRef] [Green Version]
- Storch, K.; Eke, I.; Borgmann, K.; Krause, M.; Richter, C.; Becker, K.; Schröck, E.; Cordes, N. Three-dimensional cell growth confers radioresistance by chromatin density modification. Cancer Res. 2010, 70, 3925–3934. [Google Scholar] [CrossRef] [Green Version]
- Wan, Y.; Guo, Z.; Jiang, X.; Fang, K.; Lu, X.; Zhang, Y.; Gu, N. Quasi-spherical silver nanoparticles: Aqueous synthesis and size control by the seed-mediated Lee-Meisel method. J. Colloid Interface Sci. 2013, 394, 263–268. [Google Scholar] [CrossRef]
- Damiano, J.S.; Cress, A.E.; Hazlehurst, L.A.; Shtil, A.A.; Dalton, W.S. Cell adhesion mediated drug resistance (CAM-DR): Role of integrins and resistance to apoptosis in human myeloma cell lines. Blood 1999, 93, 1658–1667. [Google Scholar] [CrossRef] [Green Version]
- Baskar, R.; Lee, K.A.; Yeo, R.; Yeoh, K.W. Cancer and radiation therapy: Current advances and future directions. Int. J. Med. Sci. 2012, 9, 193–199. [Google Scholar] [CrossRef] [Green Version]
- Formenti, S.C.; Demaria, S. Combining radiotherapy and cancer immunotherapy: A paradigm shift. J. Natl. Cancer Inst. 2013, 105, 256–265. [Google Scholar] [CrossRef] [Green Version]
- Purdy, J.A. Intensity-modulated radiotherapy: Current status and issues of interest. Int. J. Radiat. Oncol. Biol. Phys. 2001, 51, 880–914. [Google Scholar]
- Dawson, L.A.; Sharpe, M.B. Image-guided radiotherapy: Rationale, benefits, and limitations. Lancet Oncol. 2006, 7, 848–858. [Google Scholar] [CrossRef]
- Dong, X.; Luo, Z.; Liu, T.; Chai, J.; Ke, Q.; Shen, L. Identification of integrin β1 as a novel PAG1-interacting protein involved in the inherent radioresistance of human laryngeal carcinoma. J. Cancer 2018, 9, 4128–4138. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Shimura, T. Acquired Radioresistance of Cancer and the AKT/GSK3β/cyclin D1 Overexpression Cycle. J. Radiat. Res. 2011, 52, 539–544. [Google Scholar] [CrossRef] [Green Version]
- Barnett, G.C.; West, C.M.L.; Dunning, A.M.; Elliott, R.M.; Coles, C.E.; Pharoah, P.D.P.; Burnet, N.G. Normal tissue reactions to radiotherapy: Towards tailoring treatment dose by genotype. Nat. Rev. Cancer 2009, 9, 134–142. [Google Scholar] [CrossRef] [Green Version]
- Gray, M.; Turnbull, A.K.; Ward, C.; Meehan, J.; Martínez-Pérez, C.; Bonello, M.; Pang, L.Y.; Langdon, S.P.; Kunkler, I.H.; Murray, A.; et al. Development and characterisation of acquired radioresistant breast cancer cell lines. Radiat. Oncol. 2019, 14, 64. [Google Scholar] [CrossRef] [Green Version]
- Chen, X.; Chen, F.; Ren, Y.; Weng, G.; Keng, P.C.; Chen, Y.; Lee, S.O. Glucocorticoid receptor upregulation increases radioresistance and triggers androgen independence of prostate cancer. Prostate 2019, 79, 1386–1398. [Google Scholar] [CrossRef]
- Zhu, R.; Yang, X.; Xue, X.; Shen, M.; Chen, F.; Chen, X.; Tsai, Y.; Keng, P.C.; Chen, Y.; Lee, S.O.; et al. Neuroendocrine differentiation contributes to radioresistance development and metastatic potential increase in non-small cell lung cancer. Biochim. Biophys. Acta Mol. Cell Res. 2018, 1865, 1878–1890. [Google Scholar] [CrossRef]
- Moding, E.J.; Kastan, M.B.; Kirsch, D.G. Strategies for optimizing the response of cancer and normal tissues to radiation. Nat. Rev. Drug Discov. 2013, 12, 526–542. [Google Scholar] [CrossRef] [Green Version]
- Begg, A.C.; Stewart, F.A.; Vens, C. Strategies to improve radiotherapy with targeted drugs. Nat. Rev. Cancer 2011, 11, 239–253. [Google Scholar] [CrossRef]
- Johnstone, R.W. Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat. Rev. Drug Discov. 2002, 1, 287–299. [Google Scholar] [CrossRef] [PubMed]
- Gryder, B.E.; Sodji, Q.H.; Oyelere, A.K. Targeted cancer therapy: Giving histone deacetylase inhibitors all they need to succeed. Future Med. Chem. 2012, 4, 505–524. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Zhang, F.; Zhang, T.; Teng, Z.H.; Zhang, R.; Wang, J.B.; Mei, Q.B. Sensitization to γ-irradiation-induced cell cycle arrest and apoptosis by the histone deacetylase inhibitor trichostatin A in non-small cell lung cancer (NSCLC) cells. Cancer Biol. Ther. 2009, 8, 823–831. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Lytton-Jean, A.K.R.; Kauffman, K.J.; Kaczmarek, J.C.; Langer, R. Cancer nanotherapeutics in clinical trials. Cancer Treat. Res. 2015, 166, 293–322. [Google Scholar] [PubMed]
- Milane, L.; Ganesh, S.; Shah, S.; Duan, Z.F.; Amiji, M. Multi-modal strategies for overcoming tumor drug resistance: Hypoxia, the Warburg effect, stem cells, and multifunctional nanotechnology. J. Control. Release 2011, 155, 237–247. [Google Scholar] [CrossRef] [PubMed] [Green Version]
- Melamed, J.R.; Riley, R.S.; Valcourt, D.M.; Day, E.S. Using Gold Nanoparticles to Disrupt the Tumor Microenvironment: An Emerging Therapeutic Strategy. ACS Nano 2016, 10, 10631–10635. [Google Scholar] [CrossRef] [Green Version]
- Saha, S.; Xiong, X.; Chakraborty, P.K.; Shameer, K.; Arvizo, R.R.; Kudgus, R.A.; Dwivedi, S.K.D.; Hossen, M.N.; Gillies, E.M.; Robertson, J.D.; et al. Gold Nanoparticle Reprograms Pancreatic Tumor Microenvironment and Inhibits Tumor Growth. ACS Nano 2016, 10, 10636–10651. [Google Scholar] [CrossRef]
- Arvizo, R.R.; Rana, S.; Miranda, O.R.; Bhattacharya, R.; Rotello, V.M.; Mukherjee, P. Mechanism of anti-angiogenic property of gold nanoparticles: Role of nanoparticle size and surface charge. Nanomed. Nanotechnol. Biol. Med. 2011, 7, 580–587. [Google Scholar] [CrossRef] [Green Version]
- Costa, E.C.; Moreira, A.F.; de Melo-Diogo, D.; Gaspar, V.M.; Carvalho, M.P.; Correia, I.J. 3D tumor spheroids: An overview on the tools and techniques used for their analysis. Biotechnol. Adv. 2016, 34, 1427–1441. [Google Scholar] [CrossRef]
© 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
Share and Cite
Igaz, N.; Szőke, K.; Kovács, D.; Buhala, A.; Varga, Z.; Bélteky, P.; Rázga, Z.; Tiszlavicz, L.; Vizler, C.; Hideghéty, K.; et al. Synergistic Radiosensitization by Gold Nanoparticles and the Histone Deacetylase Inhibitor SAHA in 2D and 3D Cancer Cell Cultures. Nanomaterials 2020, 10, 158. https://doi.org/10.3390/nano10010158
Igaz N, Szőke K, Kovács D, Buhala A, Varga Z, Bélteky P, Rázga Z, Tiszlavicz L, Vizler C, Hideghéty K, et al. Synergistic Radiosensitization by Gold Nanoparticles and the Histone Deacetylase Inhibitor SAHA in 2D and 3D Cancer Cell Cultures. Nanomaterials. 2020; 10(1):158. https://doi.org/10.3390/nano10010158
Chicago/Turabian StyleIgaz, Nóra, Krisztina Szőke, Dávid Kovács, Andrea Buhala, Zoltán Varga, Péter Bélteky, Zsolt Rázga, László Tiszlavicz, Csaba Vizler, Katalin Hideghéty, and et al. 2020. "Synergistic Radiosensitization by Gold Nanoparticles and the Histone Deacetylase Inhibitor SAHA in 2D and 3D Cancer Cell Cultures" Nanomaterials 10, no. 1: 158. https://doi.org/10.3390/nano10010158
APA StyleIgaz, N., Szőke, K., Kovács, D., Buhala, A., Varga, Z., Bélteky, P., Rázga, Z., Tiszlavicz, L., Vizler, C., Hideghéty, K., Kónya, Z., & Kiricsi, M. (2020). Synergistic Radiosensitization by Gold Nanoparticles and the Histone Deacetylase Inhibitor SAHA in 2D and 3D Cancer Cell Cultures. Nanomaterials, 10(1), 158. https://doi.org/10.3390/nano10010158